» Articles » PMID: 34981958

A Scoping Review on the Medical and Recreational Use of Cannabis During the COVID-19 Pandemic

Overview
Specialty Pharmacology
Date 2022 Jan 4
PMID 34981958
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The shelter-in-place orders and social distancing regulations on account of the COVID-19 pandemic have impacted lifestyles, including the use of cannabis. The purpose of this scoping review is to summarize both the gray and academic literature on the use of cannabis during the pandemic. A total of 11 databases, including 2 medical databases, 7 social science databases, and 2 gray literature databases were searched resulting in 316 titles and abstracts of which 76 met inclusion criteria. Nine themes emerged: (a) prevalence and trends of cannabis use during COVID[1]19; (b) demographics; (c) profile of mode of consumption; (d) context of using cannabis (i.e., solitary use vs. in groups); (e) factors contributing to use; (f) factors inhibiting use; (g) adverse clinical and psychiatric outcomes of cannabis use during the pandemic; (h) similarities between EVALI (E-Cigarette or Vaping Product Use-Associated Lung Injury) and COVID-19 symptoms; (i) implications for policy and practice. Studies published until February 2, 2021 were included in this review. Findings have highlighted that feelings of boredom, depression, and anxiety during the pandemic have contributed to an increase in the use of cannabis. Furthermore, accessibility to cannabis was noted to affect use during the pandemic. Adverse psychiatric and clinical outcomes were associated with the increased use of cannabis. Practitioners and policymakers are called to employ harm reduction strategies to respond to increasing cannabis use. There is a need for population-based studies and further examination of factors contributing to the increased use of cannabis during the pandemic and associated negative consequences.

Citing Articles

The relationship between cannabis and cardiovascular disease: clearing the haze.

Chandy M, Jimenez-Tellez N, Wu J Nat Rev Cardiol. 2025; .

PMID: 39849111 DOI: 10.1038/s41569-025-01121-6.


Evaluating Online Cannabis Health Information for Thai Breast Cancer Survivors Using the Quality Evaluation Scoring Tool (QUEST): Mixed Method Study.

Peerawong T, Phenwan T, Makita M, Supanichwatana S, Puttarak P, Siammai N JMIR Cancer. 2024; 10:e55300.

PMID: 39727276 PMC: 11693783. DOI: 10.2196/55300.


A qualitative study of experiences among young adults who increased their cannabis use during the COVID-19 pandemic.

Struik L, Armasu A, Fortin G, Riglea T, Kalubi J, Ferlatte O BMC Public Health. 2024; 24(1):2434.

PMID: 39243042 PMC: 11380347. DOI: 10.1186/s12889-024-19886-9.


Profiles of cannabis users and impact on cannabis cessation.

MacQuarrie A, Brunelle C PLoS One. 2024; 19(6):e0305088.

PMID: 38861510 PMC: 11166302. DOI: 10.1371/journal.pone.0305088.


Maternal postpartum bonding impairment and increased substance use to cope with pandemic-related stress.

Roland A, Dressler C, Shreffler K Front Psychol. 2024; 15:1275857.

PMID: 38699571 PMC: 11064843. DOI: 10.3389/fpsyg.2024.1275857.


References
1.
Khalsa J, Bunt G, Maggirwar S, Kottilil S . COVID-19 and Cannabidiol (CBD). J Addict Med. 2020; 15(5):355-356. PMC: 8489583. DOI: 10.1097/ADM.0000000000000771. View

2.
Barratt M, Aldridge J . No magic pocket: Buying and selling on drug cryptomarkets in response to the COVID-19 pandemic and social restrictions. Int J Drug Policy. 2020; 83:102894. DOI: 10.1016/j.drugpo.2020.102894. View

3.
Hatoum A, Morrison C, Colbert S, Winiger E, Johnson E, Agrawal A . Genetic Liability to Cannabis Use Disorder and COVID-19 Hospitalization. Biol Psychiatry Glob Open Sci. 2021; 1(4):317-323. PMC: 8214324. DOI: 10.1016/j.bpsgos.2021.06.005. View

4.
Melamed O, Hauck T, Buckley L, Selby P, Mulsant B . COVID-19 and persons with substance use disorders: Inequities and mitigation strategies. Subst Abus. 2020; 41(3):286-291. DOI: 10.1080/08897077.2020.1784363. View

5.
Matthay E, Schmidt L . Home delivery of legal intoxicants in the age of COVID-19. Addiction. 2020; 116(4):691-693. PMC: 7675702. DOI: 10.1111/add.15289. View